Document is current
Any future updates will be listed below
-
Authors
Wu, Zhong
Zhou, Jin
Zhang, Xiaoyang http://orcid.org/0000-0002-0031-0290
Zhang, Zhouwei
Xie, Yingtian
Liu, Jie bin
Ho, Zandra V. http://orcid.org/0000-0003-4046-0266
Panda, Arpit
Qiu, Xintao http://orcid.org/0000-0002-8560-7017
Cejas, Paloma
Cañadas, Israel
Akarca, Fahire Goknur http://orcid.org/0000-0003-2254-3279
McFarland, James M. http://orcid.org/0000-0001-9978-480X
Nagaraja, Ankur K. http://orcid.org/0000-0002-8586-3117
Goss, Louisa B.
Kesten, Nikolas
Si, Longlong
Lim, Klothilda
Liu, Yanli
Zhang, Yanxi
Baek, Ji Yeon
Liu, Yang
Patil, Deepa T.
Katz, Jonathan P. http://orcid.org/0000-0001-6922-1707
Hai, Josephine
Bao, Chunyang http://orcid.org/0000-0001-7962-346X
Stachler, Matthew
Qi, Jun http://orcid.org/0000-0002-1461-3356
Ishizuka, Jeffrey J.
Nakagawa, Hiroshi
Rustgi, Anil K.
Wong, Kwok-Kin http://orcid.org/0000-0001-6323-235X
Meyerson, Matthew
Barbie, David A.
Brown, Myles
Long, Henry http://orcid.org/0000-0001-6849-6629
Bass, Adam J. http://orcid.org/0000-0002-8193-4758
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA196932, CA187119, CA215244)
- License Information
-
More Information
Article History
Received: 14 July 2020
Accepted: 29 March 2021
First Online: 10 May 2021
Competing interests
: A.J.B. receives research funding from Bayer, Merck and Novartis; is a consultant to Earli and HelixNano; and is a cofounder of Signet Therapeutics. K.-K.W. is a founder and equity holder of G1 Therapeutics and has consulting/sponsored research agreements with MedImmune, Takeda, TargImmune, BMS, AstraZeneca, Janssen, Pfizer, Novartis, Merck, Ono and Array. The remaining authors declare no competing interests.
